MORGAN STANLEY PLC/CALL/INCYTE CO./65/0.5/20.09.24 | Real-time Bid/Ask 09:37:17 26/06/2024 pm IST | ||
| 1.3 EUR / 1.35 EUR | -12.83% |
|
| Current month | +114.08% | ||
| 1 month | +97.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 1.3 | -14.47% |
| 25/24/25 | 1.52 | -7.32% |
| 24/24/24 | 1.64 | +14.69% |
| 21/24/21 | 1.43 | +11.72% |
| 20/24/20 | 1.28 | +14.29% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 07:05 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9GR7 |
| ISIN | DE000ME9GR71 |
| Date issued | 01/03/2024 |
| Strike | 65 $ |
| Maturity | 20/09/2024 (86 Days) |
| Parity | 2 : 1 |
| Emission price | 2.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.64 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.05 € |
| Spread % | 3.60% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
63.1
USD
Average target price
72.8
USD
Spread / Average Target
+15.37%
- Stock Market
- Warrants
- Warrant
